Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06410293 and Adalimumab Sourced From US And EU Administered To Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2014
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms REFLECTIONS B538-01
- Sponsors Pfizer
- 13 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Nov 2013 Planned End Date changed from 1 Feb 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 13 Sep 2013 Planned end date changed from 1 Jan 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.